Rocket Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Rocket Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 21 Jun 2017 | Lorem |
| Inotek’s Phase II glaucoma combination trial of trabodenoson fails to inspire expert confidence on success | 21 Jun 2017 | Alaric DeArment, Alissa Fleck |
| Inotek’s trabodenoson for glaucoma has better placement as add-on to SOC, monotherapy needs comparative data - experts | 30 Sep 2016 | Alissa Fleck |
| Inotek’s trabodenoson should hit Phase III, but placebo trial draws lackluster views on glaucoma clinical significance - experts | 29 Sep 2016 | Alissa Fleck |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer